Peritoneal Cancer Clinical Trials
Here are the 6 most popular medical studies for peritoneal cancer
Alkylating agents
Chemotherapy + Bevacizumab for Abdominal Cancer
This trial is testing a new cancer treatment combining two drugs, one given directly into the abdomen and one taken by mouth. It is for people with a certain kind of cancer that has spread into the abdomen, and who have had surgery to remove as much of the cancer as possible.
CAR T-cell Therapy
Gene-Modified T Cells for Advanced Cancers
This trial is testing the side effects and best dose of gene-modified T cells, given with or without decitabine, to treat patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced).
Popular filter options for peritoneal cancer trials
Ovarian Cancer Clinical Trials
View 75 Ovarian Cancer medical studies.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
SOC Clinical Trials
View 74 SOC medical studies.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
BRCA1 Positive Clinical Trials
View 7 BRCA1 positive medical studies.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
PARP Inhibitor
Niraparib + Dostarlimab for Cancer
This trial is testing the combination of two drugs to treat patients with BRCA-mutated cancer. Niraparib is an inhibitor of PARP, an enzyme that helps repair DNA. TSR-042 is an immunotherapy that may help the body's immune system attack the cancer.
PARP Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
BRCA2 Positive Clinical Trials
View 6 BRCA2 positive medical studies.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
PARP Inhibitor
Niraparib + Dostarlimab for Cancer
This trial is testing the combination of two drugs to treat patients with BRCA-mutated cancer. Niraparib is an inhibitor of PARP, an enzyme that helps repair DNA. TSR-042 is an immunotherapy that may help the body's immune system attack the cancer.
PARP Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
PARP Inhibitor
Tremelimumab + Olaparib for Recurrent Ovarian Cancer
This trial is testing olaparib, a PARP inhibitor, with and without tremelimumab, an immunotherapy drug, to see if they are effective in treating patients with ovarian, fallopian tube, or peritoneal cancer that has returned.
Phase 3 Peritoneal Cancer Clinical Trials
View 92 phase 3 peritoneal cancer medical studies.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Aromatase Inhibitor
Letrozole +/- Chemotherapy for Ovarian Cancer
This trial is testing whether Letrozole, with or without Paclitaxel and Carboplatin, can effectively treat patients with Stage II-IV Low-Grade Serous Carcinoma of the ovary, fallopian tube, or peritoneum.
Peritoneal Cancer Clinical Trials With No Placebo
View 92 peritoneal cancer medical studies that do not have a placebo group.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
View More Peritoneal Cancer Trials
See another 71 medical studies focused on peritoneal cancer.
Frequently Asked Questions
Introduction to peritoneal cancer
What are the top hospitals conducting peritoneal cancer research?
When it comes to cutting-edge clinical trials in the field of peritoneal cancer, several hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center has emerged as a frontrunner with an impressive 12 active peritoneal cancer trials and a total of 24 trials conducted thus far. This esteemed institution began its pioneering journey in this domain in 2005. Meanwhile, nestled in Aurora, Colorado, the University of Colorado Hospital is making significant strides with ten ongoing peritoneal cancer trials and eight completed studies since initiating their first trial also in 2005.
Roswell Park Cancer Institute located in Buffalo is another notable player with nine active clinical trials focused on peritoneal cancer; they have previously conducted seventeen investigations dating back to their very first trial recorded all the way back in 1992. UC San Diego Moores Cancer Center situated in La Jolla maintains a strong commitment to combatting this disease as well, currently undertaking seven active peritoneal cancer trials while having achieved seven previous ones since recording their inaugural trial alongside others from hospitals during that same year -2005.
Last but not least, Cedars Sinai Medical Center situated within Los Angeles demonstrates dedication by contributing valuable insights through their involvement in seven ongoing peritoneal cancer trials and four accomplished studies so far. It's noteworthy how although Cedars Sinai Medical Centre appears smaller-scale when compared to other renowned institutions mentioned earlier; its contributions should not be underestimated given that they have been able to make substantial progress despite conducting fewer overall studies from starting out during same crucial timeline-2005.
These top medical centers symbolize hope for those affected by peritoneal cancers by actively exploring new frontiers through clinical research programs worldwide teaming up together illuminating paths towards better understanding combating such ailments assuring brighter future countless patients globally who suffer these conditions.
Which are the best cities for peritoneal cancer clinical trials?
When it comes to peritoneal cancer clinical trials, several cities stand out as hubs of research and innovation. Denver, Colorado leads the way with 29 active trials focused on areas such as Quality-of-Life Assessment, Paclitaxel, and Pharmacological Study. Sacramento, California closely follows with 29 ongoing studies exploring treatments like Paclitaxel and Bevacizumab. Chicago, Illinois is another key city in this field with 28 active trials investigating Paclitaxel, Pharmacological Study, and Quality-of-Life Assessment. Anchorage in Alaska also shows promise with 27 active trials examining Letrozole, Bevacizumab, and Quality-of-Life Assessment. Los Angeles rounds up the list with 26 ongoing trials studying Paclitaxel and exploring aspects of Quality-of-Life Assessment among other approaches. These cities provide individuals fighting peritoneal cancer access to cutting-edge clinical trials that hold potential for improved outcomes and better quality of life.
Which are the top treatments for peritoneal cancer being explored in clinical trials?
Clinical trials for peritoneal cancer have identified several top treatments that show promise in fighting this challenging disease. Paclitaxel, a drug first listed in 2002, is leading the pack with nine active trials and an impressive track record of 40 all-time peritoneal cancer trials. Additionally, pharmacological studies are being conducted in four ongoing trials to explore new avenues of treatment. Quality-of-life assessments also play a crucial role, with four active trials dedicated to understanding the impact of various interventions on patients' well-being. Lastly, olaparib stands out as a potential game-changer, currently being tested in three active clinical trials for peritoneal cancer since its introduction in 2016. As researchers delve deeper into these innovative approaches, hope shines brighter for individuals battling this complex form of cancer.
What are the most recent clinical trials for peritoneal cancer?
Exciting developments in clinical trials offer hope for individuals diagnosed with peritoneal cancer. The mEPIC trial, a Phase 2 study, presents an opportunity to explore innovative approaches in the treatment of this disease. Additionally, the IP FT538 + Enoblituzumab trial investigates the potential benefits of combining different therapies for peritoneal cancer patients. Another promising avenue is examined through the Pembrolizumab and Vismodegib trials, both in Phase 2, which aim to assess the effectiveness of these drugs against peritoneal cancer. Finally, a combination therapy involving Chemotherapy + BEV + IMNN-001 shows promise as it progresses through Phases 1 and 2 of its clinical trial journey. These recent studies mark significant strides towards improving outcomes and enhancing treatment options for those affected by peritoneal cancer.
What peritoneal cancer clinical trials were recently completed?
Several noteworthy clinical trials investigating treatments for peritoneal cancer have achieved significant milestones, bringing hope to patients battling this challenging disease. One recent completion in November 2021 was the trial sponsored by OncoNano Medicine, Inc., which explored the potential of pegsitacianine therapy. Furthermore, a study led by Dan Blazer III, M.D., concluded in May 2019 and focused on Talimogene Laherparepvec's effectiveness against peritoneal cancer. Other notable completed trials include Atezolizumab (March 2017) sponsored by Hoffmann-La Roche, Rucaparib (March 2017) sponsored by Clovis Oncology, Inc., Hyperthermic Intraperitoneal Chemotherapy (September 2016) conducted at M.D. Anderson Cancer Center and Oxaliplatin (July 2016) spearheaded by the University of Massachusetts Worcester. These advancements highlight ongoing efforts to improve outcomes for individuals affected by peritoneal cancer.